RecruitingProstate Cancer After a Radical TreatmentBiochemical Recurrence of Malignant Neoplasm of ProstateBiochemical Persistence of Prostate Cancer
Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
Eligible age
18+ yrs
Accepts
Men
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.
Sponsor: Heinrich-Heine University, Duesseldorf
You may qualify if…
- ✓ Informed Consent
- ✓ Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care
You may not qualify if…
- ✕ Technical Flaws in the acquisition protocol
Source: ClinicalTrials.gov · NCT06657131 · last updated 2025-01-17